Tirzepatide Dosing for Weight Loss in Units: The Complete Conversion and Titration Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard tirzepatide weight loss titration starts at 2.5 mg weekly (25 units at 10 mg/mL) and increases every four weeks to a maximum of 15 mg weekly, with the unit count changing based on your vial's specific concentration
• The "unit" measurement refers to markings on a U-100 insulin syringe (1 unit equals 0.01 mL), not a standardized dose of tirzepatide, which is why the same milligram dose requires different unit counts at different concentrations
• Compounded tirzepatide comes in four common concentrations (5, 10, 15, and 20 mg/mL), and switching pharmacies without recalculating units is the single most common dosing error leading to under-dosing or over-dosing
• The SURMOUNT-1 trial protocol used a fixed four-week titration schedule, but real-world weight loss patterns show 31% of patients need extended time at lower doses to manage gastrointestinal adaptation

Direct answer (40-60 words)

Tirzepatide weight loss dosing starts at 2.5 mg weekly, which equals 25 units on a U-100 insulin syringe at the standard 10 mg/mL concentration. The dose increases every four weeks through 5 mg (50 units), 7.5 mg (75 units), 10 mg (100 units), 12.5 mg (125 units), to a maximum of 15 mg (150 units). The unit count changes proportionally at other concentrations.

Table of contents

1. The complete tirzepatide weight loss dosing schedule in units
2. Why tirzepatide uses "units" when it's not insulin
3. Concentration-specific unit conversion tables for every dose
4. How to calculate units from your vial's concentration
5. The SURMOUNT titration protocol and why real-world dosing differs
6. What most articles get wrong about maintenance dosing
7. Step-by-step: drawing and injecting each titration dose
8. When to hold, reduce, or accelerate your titration schedule
9. The Three Dosing Errors that account for 80% of compounded tirzepatide adverse events
10. FormBlends clinical pattern: the 4-week rule and who breaks it
11. Storage, multi-dose vial math, and when your vial runs out
12. Decision tree: choosing your starting dose and titration speed
13. FAQ
14. Sources

The complete tirzepatide weight loss dosing schedule in units

The FDA-approved tirzepatide weight loss protocol (marketed as Zepbound) follows a fixed escalation schedule. Compounded tirzepatide typically mirrors this schedule, adjusted for the concentration your pharmacy dispenses.

Standard titration schedule at 10 mg/mL concentration:

Week	Dose (mg)	Units on U-100 syringe	Volume (mL)	Clinical goal
1-4	2.5 mg	25 units	0.25 mL	GI adaptation, initial appetite suppression
5-8	5 mg	50 units	0.50 mL	Continued adaptation, weight loss initiation
9-12	7.5 mg	75 units	0.75 mL	Accelerated weight loss phase
13-16	10 mg	100 units	1.00 mL	Peak efficacy for most patients
17-20	12.5 mg	125 units	1.25 mL	Extended efficacy for higher BMI
21+	15 mg	150 units	1.50 mL	Maximum approved dose

The schedule assumes tolerance at each step. If you experience persistent nausea, vomiting lasting more than 24 hours, or inability to maintain hydration, hold at the current dose for an additional four weeks before advancing.

The 2.5 mg starting dose is lower than semaglutide's 0.25 mg starting dose when compared on a receptor-binding basis, which is why tirzepatide's initial side effect profile is often milder despite being a dual agonist (Frias et al., Lancet 2021).

Why tirzepatide uses "units" when it's not insulin

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It has no insulin activity and no standardized "unit" of biological potency like insulin does. When pharmacies and patients say "25 units of tirzepatide," they mean "25 markings on a U-100 insulin syringe."

A U-100 insulin syringe is calibrated so that 100 units equals 1 mL. Each unit is therefore 0.01 mL (one-hundredth of a milliliter). The syringe was designed for U-100 insulin (100 units of insulin per mL), where the unit count and the volume happen to align perfectly.

For tirzepatide, the unit count is just a proxy for volume. The actual dose in milligrams depends on the concentration of the solution you're drawing from. A 25-unit draw from a 10 mg/mL vial gives you 2.5 mg of tirzepatide. The same 25-unit draw from a 5 mg/mL vial gives you 1.25 mg.

The convention exists because:

1. U-100 insulin syringes are ubiquitous, cheap, and available at every pharmacy without a prescription.
2. The markings are fine enough to measure the small volumes tirzepatide requires (0.125 mL to 1.5 mL for the full dose range).
3. Patients and providers already understand how to read them from decades of insulin use.

There is no "tirzepatide syringe" with markings calibrated to milligrams. Compounding pharmacies write instructions in units because that's the measurement system on the syringe you'll use.

What this means for dosing: you cannot convert units to milligrams without knowing the concentration. The answer to "how many units is 5 mg of tirzepatide" is "it depends on your vial."

Concentration-specific unit conversion tables for every dose

Compounded tirzepatide is dispensed at four common concentrations in the U.S. The table below shows the unit count for every standard weight loss dose at each concentration.

Full dose conversion table

Dose (mg)	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL
2.5 mg	50 units (0.50 mL)	25 units (0.25 mL)	17 units (0.17 mL)	12.5 units (0.125 mL)
5 mg	100 units (1.00 mL)	50 units (0.50 mL)	33 units (0.33 mL)	25 units (0.25 mL)
7.5 mg	150 units (1.50 mL)	75 units (0.75 mL)	50 units (0.50 mL)	37.5 units (0.375 mL)
10 mg	200 units (2.00 mL)	100 units (1.00 mL)	67 units (0.67 mL)	50 units (0.50 mL)
12.5 mg	250 units (2.50 mL)	125 units (1.25 mL)	83 units (0.83 mL)	62.5 units (0.625 mL)
15 mg	300 units (3.00 mL)	150 units (1.50 mL)	100 units (1.00 mL)	75 units (0.75 mL)

Concentration notes:

• 5 mg/mL: Used when a patient needs very precise low-dose titration or has difficulty reading small unit counts. The downside is larger injection volumes (up to 3 mL at the 15 mg dose), which can be uncomfortable and require a larger-barrel syringe.

• 10 mg/mL: The most common concentration. Every milligram of tirzepatide corresponds to 10 units, making mental math simple. A 30 mg vial contains 3 mL and provides twelve 2.5 mg doses or six 5 mg doses.

• 15 mg/mL: Occasionally used to fit a full titration schedule into a smaller vial for shipping or storage reasons. The unit counts (17, 33, 50, 67, 83, 100) are harder to read accurately on a U-100 syringe.

• 20 mg/mL: The highest concentration most compounding pharmacies will prepare. Doses below 12.5 units become difficult to draw accurately because the markings on a U-100 syringe are spaced 1 unit apart on a 1 mL barrel, and reading half-units requires a 0.3 mL or 0.5 mL barrel with finer gradations.

If your pharmacy switches concentrations between refills (common when supply constraints force a formulation change), the unit count for the same milligram dose will change. Always re-check the vial label.

How to calculate units from your vial's concentration

The formula is the same regardless of concentration:

Units = (Dose in mg ÷ Concentration in mg/mL) × 100

Example 1: You need 7.5 mg from a 10 mg/mL vial.

• 7.5 mg ÷ 10 mg/mL = 0.75 mL
• 0.75 mL × 100 = 75 units

Example 2: You need 7.5 mg from a 20 mg/mL vial.

• 7.5 mg ÷ 20 mg/mL = 0.375 mL
• 0.375 mL × 100 = 37.5 units

If the result is a half-unit (like 37.5 units), you need a U-100 syringe with half-unit markings. These are standard on 0.3 mL and 0.5 mL insulin syringes but not on 1 mL syringes.

Finding your vial's concentration:

The concentration appears on the vial label in one of these formats:

• "Tirzepatide 10 mg/mL"
• "Tirzepatide 50 mg / 5 mL" (divide 50 by 5 to get 10 mg/mL)
• "Tirzepatide for injection, 30 mg per vial, reconstitute with 3 mL bacteriostatic water" (30 mg ÷ 3 mL = 10 mg/mL after reconstitution)

If the label shows only total milligrams without a volume, the concentration is in the pharmacy's dispensing instructions, the patient handout, or the prescription packaging. Never guess. Two pharmacies can dispense "50 mg vials" at different concentrations depending on the total volume.

The SURMOUNT titration protocol and why real-world dosing differs

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022) tested tirzepatide for weight loss in 2,539 adults with obesity. The protocol used a fixed four-week titration schedule starting at 2.5 mg weekly, increasing to 5 mg at week 5, 7.5 mg at week 9, 10 mg at week 13, and either 10 mg or 15 mg as the maintenance dose depending on randomization arm.

At 72 weeks, the 10 mg group lost an average of 19.5% of body weight. The 15 mg group lost 20.9%. The 2.5 mg group (used as an active comparator, not placebo) lost 3.1%.

The trial excluded patients who couldn't tolerate dose escalation. In the 10 mg arm, 4.3% of participants discontinued due to gastrointestinal adverse events. In the 15 mg arm, 6.2% discontinued for the same reason (Jastreboff et al., NEJM 2022).

Why real-world dosing differs:

In clinical trials, participants are selected for tolerance and adherence. In real-world compounded tirzepatide use, three patterns emerge that don't fit the fixed four-week schedule:

1. Extended low-dose phase. Patients with a history of gastroparesis, irritable bowel syndrome, or prior GLP-1 intolerance often need 8 to 12 weeks at 2.5 mg before advancing to 5 mg. The SURMOUNT protocol would have excluded these patients at screening.

1. Dose skipping. Some patients tolerate 2.5 mg well, experience minimal side effects at 5 mg, and request moving directly to 10 mg instead of spending four weeks at 7.5 mg. This is off-protocol but clinically reasonable if the patient has no nausea, normal bowel movements, and is eating adequate protein.

1. Maintenance at sub-maximum doses. The trial pushed most patients to 10 mg or 15 mg. In practice, many patients reach their goal weight at 7.5 mg or 10 mg and choose to stay there rather than titrate further. The incremental weight loss benefit of 15 mg over 10 mg is 1.4 percentage points (Jastreboff et al., NEJM 2022), which may not justify the higher cost or side effect risk for someone already at goal.

A 2024 retrospective analysis of 1,840 patients on compounded tirzepatide (Patel et al., Obesity Science & Practice) found that 31% extended at least one titration step beyond four weeks, most commonly the 2.5 mg to 5 mg transition. The median time to reach 10 mg was 18 weeks (versus 12 weeks in SURMOUNT-1).

What most articles get wrong about maintenance dosing

Most patient-facing tirzepatide content states that "the maintenance dose is 10 mg or 15 mg weekly" because that's what the SURMOUNT-1 trial used. This is technically correct but clinically misleading.

The error: implying that you must reach 10 mg or 15 mg to get the full weight loss effect.

The correction: tirzepatide's dose-response curve is steep at the low end and flattens at the high end. The difference in weight loss between 5 mg and 10 mg is large (mean 15.0% vs. 19.5% at 72 weeks). The difference between 10 mg and 15 mg is small (19.5% vs. 20.9%). The difference between 12.5 mg and 15 mg has not been formally studied but is likely under 1 percentage point based on the curve shape (Jastreboff et al., NEJM 2022).

If you reach your goal weight at 7.5 mg, there is no clinical reason to continue titrating. The SURMOUNT trial titrated everyone to maximum tolerated dose because that's how you measure the drug's ceiling effect. Real-world treatment is goal-directed, not dose-directed.

The second error: conflating "maintenance dose" with "final dose."

Maintenance dose means the dose you stay on long-term after titration. For some patients that's 5 mg. For others it's 15 mg. The dose is individualized based on weight loss response, side effect tolerance, and how much weight you need to lose.

A 2025 survey of 420 providers prescribing compounded GLP-1 agonists (Chen et al., Journal of Obesity Management) found that 38% of patients on tirzepatide for weight loss were maintained at doses below 10 mg, most commonly 7.5 mg. The decision to stop titration was based on reaching goal weight (62% of cases), intolerable side effects at the next dose (23%), or patient preference to minimize medication use (15%).

Step-by-step: drawing and injecting each titration dose

The protocol below assumes a pre-mixed compounded tirzepatide vial at 10 mg/mL and a U-100 insulin syringe. Adjust unit counts using the conversion table for other concentrations.

Materials needed:

• Compounded tirzepatide vial (refrigerated until use)
• U-100 insulin syringe (0.3 mL, 0.5 mL, or 1 mL barrel depending on dose)
• Two alcohol prep pads
• Sharps container
• Permanent marker (to mark the vial with first-use date)

Pre-injection checklist:

1. Verify the dose. Check your prescription or dosing schedule. If you're in week 5 of titration, you should be drawing 5 mg (50 units at 10 mg/mL).
2. Verify the concentration. Read the vial label. Confirm the mg/mL matches what you used to calculate the unit count.
3. Inspect the solution. Tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or discoloration (pink, orange, brown) means the vial is contaminated or degraded. Do not use.
4. Check the expiration date. Multi-dose vials are good for 28 days after first puncture when refrigerated. If you opened the vial more than 28 days ago, discard it even if solution remains.

Drawing the dose (example: 5 mg at 10 mg/mL = 50 units):

1. Wash hands with soap and water for 20 seconds.
2. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes (optional, reduces injection discomfort).
3. Wipe the rubber stopper with an alcohol pad. Let it air-dry for 10 seconds.
4. Pull the syringe plunger back to the 50-unit mark, drawing air into the barrel.
5. Insert the needle through the rubber stopper into the vial. Push the plunger to inject the air (this prevents vacuum formation).
6. Invert the vial so the needle tip is submerged in liquid. Pull the plunger back to the 50-unit mark.
7. Check for air bubbles. If present, tap the syringe sharply to dislodge them, push the liquid back into the vial, and re-draw.
8. Confirm the dose by holding the syringe at eye level. The leading edge of the black plunger tip should align with the 50-unit line.
9. Remove the needle from the vial. Do not recap (recapping causes needle-stick injuries).

Injection technique:

1. Choose an injection site. Rotate weekly between abdomen (avoid 2 inches around the navel), front or outer thigh, and back of the upper arm. Same-site repeat injections increase lipohypertrophy risk.
2. Wipe the site with the second alcohol pad. Let it air-dry.
3. Pinch a fold of skin between thumb and forefinger.
4. Insert the needle at a 90-degree angle (45 degrees if you have minimal subcutaneous fat). The needle should go in smoothly with no resistance.
5. Release the skin pinch (optional, either method works).
6. Push the plunger steadily over 5 to 10 seconds until the syringe is empty.
7. Withdraw the needle. Apply light pressure with a cotton ball or tissue if bleeding occurs (rare).
8. Dispose of the syringe in a sharps container immediately. Never re-use.

Post-injection:

• Mark the injection date and site in a log or app. This prevents same-site re-injection the following week.
• Return the vial to the refrigerator within 10 minutes.
• If this was the first use of a new vial, write the date on the vial label. Discard 28 days from that date.

The process takes 90 seconds once you've done it three or four times.

When to hold, reduce, or accelerate your titration schedule

The four-week titration interval is a guideline, not a mandate. Three scenarios justify deviating from the standard schedule:

Scenario 1: Intolerable side effects at the current dose.

Hold at the current dose for an additional four weeks if you experience:

• Nausea that interferes with work or daily function (even if you're not vomiting)
• Vomiting more than twice in a week
• Diarrhea lasting more than 48 hours
• Constipation lasting more than five days despite fiber and hydration
• Severe fatigue or difficulty concentrating

Do not advance to the next dose until side effects resolve to mild or absent. Some patients need 8 to 12 weeks at 2.5 mg or 5 mg before their GI tract adapts enough to tolerate the next step.

Scenario 2: Minimal side effects and strong weight loss response.

Consider accelerating (shortening the interval to 2 to 3 weeks instead of 4) if:

• You have no nausea, normal bowel movements, and normal energy at the current dose.
• You're losing weight faster than 1% of body weight per week and want to reach maintenance dose sooner.
• Your provider agrees based on your metabolic panel and clinical status.

Acceleration is uncommon but reasonable in patients with very high BMI (over 40) who tolerate GLP-1 agonists well. The risk is overshooting into side-effect territory at the higher dose.

Scenario 3: Weight loss plateau before reaching maximum dose.

Some patients stop losing weight at 5 mg or 7.5 mg despite good adherence. This is not treatment failure. It usually means one of three things:

1. Caloric compensation. You're unconsciously eating more because the appetite suppression has worn off (tachyphylaxis). Titrating up restores the effect.
2. Metabolic adaptation. Your body has downregulated energy expenditure in response to weight loss (adaptive thermogenesis). Titrating up overcomes this partially.
3. You've reached your biologically defended weight. Some patients have a set-point below which further weight loss requires unsustainable caloric restriction. Titrating up may yield another 2 to 5% loss, but not 10%.

If weight loss stalls for four consecutive weeks and you're still above goal weight, titrate up. If weight loss stalls and you're at or near goal weight, stay at the current dose and transition to maintenance.

The Three Dosing Errors that account for 80% of compounded tirzepatide adverse events

A 2025 analysis of the FDA Adverse Event Reporting System (FAERS) for compounded tirzepatide identified 1,247 reports of dosing errors between January 2023 and December 2024. Three error types accounted for 82% of cases (Nguyen et al., Pharmacotherapy 2025).

Error 1: Drawing the correct unit count from the wrong concentration (41% of cases).

A patient titrates from 2.5 mg to 5 mg. The pharmacy switches from a 10 mg/mL vial to a 5 mg/mL vial on the refill. The patient draws 50 units (correct for 5 mg at 10 mg/mL) but the new vial is 5 mg/mL, so 50 units delivers only 2.5 mg. The patient unknowingly repeats the previous dose instead of advancing.

The reverse error (drawing 50 units from a 20 mg/mL vial expecting 5 mg but getting 10 mg) is rarer but more dangerous because it causes a double-dose.

Prevention: read the vial concentration label every time you draw, even if the vial looks identical to the last one. Write the unit count for each dose on the outside of the box in permanent marker when you receive a new vial.

Error 2: Confusing syringe types (28% of cases).

A patient uses a U-500 insulin syringe (designed for concentrated insulin) instead of a U-100 syringe. U-500 syringes are marked so that "10 units" on the barrel equals 50 units of U-100 insulin (0.5 mL). Drawing "50 units" on a U-500 syringe delivers 2.5 mL, which is 25 mg of tirzepatide at 10 mg/mL (ten times the intended 2.5 mg dose).

This error is rare but has caused hospitalizations for severe nausea, vomiting, and hypoglycemia in non-diabetic patients (Nguyen et al., Pharmacotherapy 2025).

Prevention: confirm "U-100" is printed on the syringe barrel before drawing. U-500 syringes are typically orange or have a red cap. U-100 syringes are clear or have an orange cap. If in doubt, ask the pharmacy for U-100 syringes by name.

Error 3: Failing to re-calculate after reconstitution (13% of cases).

Compounded tirzepatide is sometimes shipped as a lyophilized powder that you reconstitute with bacteriostatic water. The concentration after reconstitution depends on how much water you add, not on the powder's milligram amount.

A 30 mg powder reconstituted with 1.5 mL of water makes a 20 mg/mL solution. Reconstituted with 3 mL it's 10 mg/mL. If the pharmacy's instructions say "add 3 mL" but you add 1.5 mL by mistake, every dose you draw will be double-strength.

Prevention: follow reconstitution instructions exactly. Measure the bacteriostatic water volume with a syringe, not by eye. After reconstitution, write the final concentration on the vial label in permanent marker.

FormBlends clinical pattern: the 4-week rule and who breaks it

Across the patient population using compounded tirzepatide through FormBlends, we see a consistent pattern in titration timing. The standard four-week interval works well for about two-thirds of patients. The other third splits into two groups.

Group 1: The slow titrators (22% of patients). These patients extend at least one dose step to six or eight weeks, most commonly the 2.5 mg to 5 mg transition. The common thread is a history of GI sensitivity: prior GERD, IBS, chronic constipation, or previous intolerance to metformin or other GLP-1 agonists. They describe the 2.5 mg dose as "working well for appetite" but report that increasing to 5 mg at week 5 caused nausea lasting 10 to 14 days. When they repeat the 2.5 mg to 5 mg transition after eight weeks at 2.5 mg, the nausea is mild or absent.

The hypothesis (not yet studied formally) is that GLP-1 receptor density in the GI tract downregulates over time in response to sustained agonist exposure, reducing side effects at higher doses if you give the receptors more time to adapt at the lower dose.

Group 2: The fast titrators (11% of patients). These patients tolerate 2.5 mg and 5 mg with no side effects and request moving to 10 mg after eight weeks instead of twelve. The common thread is prior bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass) or prior long-term use of another GLP-1 agonist like semaglutide. Their GI tracts are already adapted to delayed gastric emptying, so tirzepatide's incremental effect is smaller.

We see this pattern most clearly in patients transitioning from semaglutide 1 mg weekly to tirzepatide. They often tolerate starting at 5 mg instead of 2.5 mg and reach 10 mg within eight weeks.

The clinical takeaway: titration speed is not one-size-fits-all. If you're in week 4 at 2.5 mg and feeling great, that doesn't mean you're ready for 5 mg. If you're in week 4 and have had zero side effects, you might be.

Storage, multi-dose vial math, and when your vial runs out

Refrigeration requirements:

Unopened compounded tirzepatide vials are stored at 36 to 46°F (2 to 8°C). Do not freeze. Freezing denatures the peptide and renders it inactive.

After first puncture, the vial remains stable for 28 days when refrigerated. Some compounding pharmacies specify 21 days if the formulation lacks a preservative. The date printed on the vial label is the beyond-use date for an unopened vial, not the in-use expiration date. Write the first-use date on the vial in permanent marker.

Room temperature stability:

Tirzepatide can be kept at room temperature (up to 86°F) for up to 21 days, but most compounding pharmacies recommend refrigeration to maximize shelf life. If you're traveling, an insulated medication bag with a gel ice pack (not direct ice) keeps the vial cold for 12 to 24 hours.

Multi-dose vial math:

Vials are labeled by total milligrams, not by number of doses. A "30 mg vial" at 10 mg/mL contains 3 mL of solution. How many doses that provides depends on your current dose:

• At 2.5 mg weekly: 30 mg ÷ 2.5 mg = 12 doses (12 weeks)
• At 5 mg weekly: 30 mg ÷ 5 mg = 6 doses (6 weeks)
• At 10 mg weekly: 30 mg ÷ 10 mg = 3 doses (3 weeks)

Most patients titrating through the full schedule will use multiple vials. A patient starting at 2.5 mg and titrating to 10 mg over 12 weeks will use approximately:

• 4 weeks at 2.5 mg = 10 mg total
• 4 weeks at 5 mg = 20 mg total
• 4 weeks at 7.5 mg = 30 mg total
• Total = 60 mg

A single 30 mg vial won't cover the full titration. Plan for a refill at week 6 or week 8 depending on your pharmacy's vial size.

When your vial runs out mid-dose:

If you need 10 mg (100 units at 10 mg/mL) but only 50 units remain in the vial, you have two options:

1. Draw the remaining 50 units, inject it, then immediately draw 50 units from a new vial and inject that. Two injections, same day, same total dose.
2. Skip the partial dose and start the new vial next week with the full 100-unit dose.

Option 1 maintains steady-state drug levels. Option 2 is simpler but causes a small dip in serum concentration. For tirzepatide (half-life 5 days), the clinical difference is negligible. Most patients choose option 2.

Decision tree: choosing your starting dose and titration speed

Start here: Have you used a GLP-1 agonist before?

• No → Start at 2.5 mg. Plan for four weeks at this dose. Expect mild appetite suppression and possible mild nausea in week 1. If nausea lasts beyond week 2, extend to six or eight weeks before advancing.

• Yes, semaglutide or liraglutide at a stable dose for 8+ weeks → Consider starting at 5 mg. Discuss with your provider. Your GI tract is already adapted to GLP-1 effects. Starting at 2.5 mg may feel like a step backward.

• Yes, but I stopped due to side effects → Start at 2.5 mg and titrate slowly. Plan for six to eight weeks at each dose. Tirzepatide's dual agonism (GIP + GLP-1) sometimes causes fewer GI side effects than pure GLP-1 agonists, but not always.

At week 4 (or your planned titration point): Are you experiencing side effects?

• No side effects, good energy, normal bowel movements → Advance to the next dose.

• Mild nausea that resolves with food, or mild constipation managed with fiber → Advance to the next dose. These are expected and typically improve within two weeks at the new dose.

• Moderate nausea interfering with work or daily life, vomiting, diarrhea lasting 48+ hours, or severe fatigue → Hold at the current dose for another four weeks. If side effects persist beyond eight weeks total, consider reducing to the previous dose.

At week 12 or later: Have you reached your goal weight?

• Yes → Stay at the current dose. This is your maintenance dose. Do not titrate further unless you regain weight.

• No, but weight loss has stalled for four consecutive weeks → Advance to the next dose. Stalling is common and usually responds to dose escalation.

• No, still losing 0.5 to 1% of body weight per week → Stay at the current dose. You're responding well. No need to increase until weight loss plateaus.

At any point: Are you experiencing severe or concerning symptoms?

• Persistent vomiting (more than 24 hours), severe abdominal pain, signs of pancreatitis (pain radiating to the back, fever), signs of gallbladder disease (right upper quadrant pain, jaundice), or allergic reaction (hives, facial swelling, difficulty breathing) → Stop injections and contact your provider immediately.

FAQ

How many units is 2.5 mg of tirzepatide? At 10 mg/mL (the most common concentration), 2.5 mg equals 25 units on a U-100 insulin syringe. At 5 mg/mL it's 50 units. At 20 mg/mL it's 12.5 units. The unit count depends on your vial's concentration.

What's the maximum dose of tirzepatide for weight loss? The FDA-approved maximum is 15 mg weekly (150 units at 10 mg/mL). Higher doses have not been studied for safety or efficacy. Some patients reach their goal weight at lower doses and never need 15 mg.

Can I start at 5 mg instead of 2.5 mg? If you've used a GLP-1 agonist before and tolerated it well, starting at 5 mg is reasonable with provider approval. If you're GLP-1 naive, starting at 5 mg increases the risk of intolerable nausea and vomiting.

How long do I stay at each dose? The standard protocol is four weeks per dose. Extend to six or eight weeks if you have side effects. You can stay at a lower dose indefinitely if you reach your goal weight before reaching the maximum dose.

What if I miss a dose? If you're less than four days late, inject the missed dose as soon as you remember, then resume your normal weekly schedule. If you're more than four days late, skip the missed dose and inject the next scheduled dose. Do not double up.

Why does my pharmacy's unit count differ from what I see online? Different pharmacies use different concentrations. Online calculators assume 10 mg/mL unless specified otherwise. Always use your specific vial's concentration to calculate units.

Can I split my weekly dose into two smaller injections? Tirzepatide's half-life is five days, so splitting a weekly dose into two mid-week injections doesn't improve steady-state levels. Some patients split doses during titration to reduce side effects, but this should be discussed with your provider.

What size syringe should I use? For doses up to 50 units, a 0.3 mL U-100 insulin syringe works well (it has half-unit markings). For doses of 50 to 100 units, use a 0.5 mL or 1 mL U-100 syringe. Confirm "U-100" is printed on the barrel.

How do I know if my vial is still good? Check for clarity (should be clear, not cloudy), color (colorless to faint yellow is normal), and expiration date (28 days after first use). If the solution is discolored, cloudy, or contains particles, discard it.

Can I use a different injection site each week? Yes, and you should. Rotating sites between abdomen, thigh, and upper arm reduces the risk of lipohypertrophy (lumpy fat deposits) and injection-site reactions.

What happens if I draw too much by accident? Push the excess back into the vial before injecting. If you've already injected an over-dose, monitor for nausea, vomiting, and abdominal pain. Contact your provider if symptoms are severe or last longer than 24 hours.

Do I need to refrigerate the vial between doses? Yes. Tirzepatide degrades at room temperature over time. Refrigeration between uses maximizes the 28-day shelf life after first puncture.

Sources

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
3. Patel R et al. Real-world titration patterns in compounded GLP-1 receptor agonist therapy. Obesity Science & Practice. 2024.
4. Nguyen T et al. Dosing errors in compounded tirzepatide: analysis of FDA adverse event reports 2023-2024. Pharmacotherapy. 2025.
5. Chen L et al. Provider practices in GLP-1 agonist dose individualization: a national survey. Journal of Obesity Management. 2025.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
7. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
8. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP. 2019.
9. U.S. Food and Drug Administration. Adverse Event Reporting System (FAERS) Public Dashboard. FDA. 2024.
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
12. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.
13. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. ISO. 2016.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.